보고서 (영문) | |
제약/바이오/ 임상시험 |
Janssen Gains Approval for Rybrevant as First-Line Treatment for NSCLC Subtype |
Innovent’s ROS1 TKI Is One Step Closer to Winning the Chinese NSCLC Market | |
FLOW Trial Sheds Positive Light on Ozempic for CKD | |
GLP1 Agonists to Surpass PD1 Antagonists as the Best Selling Drugs in 2024 and Beyond | |
IO360: Phase II Trial Reveals Motixafortide's Efficacy in First-Line Pancreatic Cancer Treatment | |
RNA-Based Drugs and the Impact of COVID-19 | |
Eli Lilly’s Partnership with Amazon to Boost Presence in Diabetes and Obesity Markets | |
Padcev, Keytruda, and Balversa Leave Little Room for Opdivo in Urothelial Carcinoma | |
질환별 | Polycystic Ovarian Syndrome: Competitive Landscape |
Cases of Tuberculosis Could Exceed Pre-Pandemic Numbers in England | |
TB Potentially Transmissible in Undiagnosed Cases | |
Cell & Gene Therapies in CNS Disorders | |
Artificial Intelligence Identified Two Evolutionary Pathways of Prostate Cancer | |
Female Vitiligo Patients Are at an Increased Risk of Osteoporosis | |
Lung Cancer Deaths Have Declined Sharply in UK Middle-Aged Adults | |
컨퍼런스/ 심포지엄/ 학회/기타 |
AD/PD 2024: Early Diagnosis Remains a Hurdle for DMT in Parkinson’s |
AD/PD 2024: The Role of Blood-Based Biomarkers in Alzheimer’s Disease | |
AD/PD 2024: Promise for TauRx’s HMTM, Despite Lacking Primary Endpoint Data | |
AD/PD 2024: Cell Therapies Show Promise for Parkinson’s Disease Non-motor Symptoms | |
AD/PD 2024: Eli Lilly’s Donanemab Hit with FDA Delay | |
AD/PD 2024: Leqembi Data Supports Early Treatment Initiation for Better Outcomes | |
AD/PD 2024: BioVie’s Novel NE3107 Shows Promise but Confirmatory Trial Needed | |
AD/PD 2024: Exploring Cutting-Edge Therapies for Amyotrophic Lateral Sclerosis | |
Defining the HTA Landscape for France and Germany: 2019–23 | |
Highlights from the IO360 Conference: PD-1 Inhibitors and Systemic Oncolytic Viral Immunotherapies | |
New NIH Cancer Screening Research Network to Evaluate Screening Technologies | |
BIOSECURE Act Could Impact WuXi-Manufactured Drugs for the US Market | |
Clinical Trial Decline Highlights a Lack of Incentives for Drug Manufacturers |
'의료기기관련기관 > 국가임상시험지원재단' 카테고리의 다른 글
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 4.24. (수) (0) | 2024.09.15 |
---|---|
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 안내 4.12. (금) (0) | 2024.09.15 |
해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 (0) | 2024.08.02 |
[KoNECT] 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 (0) | 2024.03.15 |
[KoNECT] 해외 임상시험 정보 데이터(GlobalData) 보고서 업데이트 (0) | 2024.03.15 |